Showing results 4 to 10 of 10
< previous
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Hepatology | 2011 | 218 | ||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | 88 | ||
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research | 2018 | 50 | ||
2021 | 25 | |||
2017 | 54 | |||
2015 | 50 | |||
2016 | 74 |